The development of new chemotherapeutic agents

被引:0
|
作者
Hanauske, AR
机构
关键词
LY231514; raltitrexed (Tomudex(R)); trimetrexate; gemcitabine; CPT-11;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
There is a great need for new drugs to treat the increasing numbers of patients with disseminated cancers. Many of the known anticancer drugs, including the taxoids, docetaxel (Taxotere(R)) and paclitaxel (Taxol(R)), are derived from natural products and there will be many more active compounds to be discovered amongst the 300 000 plant species available for evaluation. Cytotoxic agents may kill cancer cells by a variety of means. Thymidilate synthase inhibitors such as LY231514 and raltitrexed (Tomudex(R)) have shown activity against a variety of solid tumours including colorectal cancer. The antifolate, trimetrexate, and the nucleoside analogue, gemcitabine, have also shown anticancer activity. Amongst the topoisomerase I inhibitors, CPT-11 is being developed for use against colorectal cancer. Non-cytotoxic agents which interfere with processes such as angiogenesis may also have a role in future treatments for disseminated cancers.
引用
收藏
页码:29 / 32
页数:4
相关论文
共 50 条
  • [31] NEW CHEMOTHERAPEUTIC-AGENTS FOR BREAST-CANCER
    ABRAMS, JS
    MOORE, TD
    FRIEDMAN, M
    CANCER, 1994, 74 (03) : 1164 - 1176
  • [32] Perspectives on new chemotherapeutic agents in the treatment of colorectal cancer
    Clark, JW
    SEMINARS IN ONCOLOGY, 1997, 24 (05) : 19 - 24
  • [33] The Value of New Chemotherapeutic Agents for Metastatic Colorectal Cancer
    Howard, David H.
    Kauh, John
    Lipscomb, Joseph
    ARCHIVES OF INTERNAL MEDICINE, 2010, 170 (06) : 537 - 542
  • [34] Malarial protease inhibitors: Potential new chemotherapeutic agents
    Sharma, Arun
    CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2007, 8 (08) : 642 - 652
  • [35] Thermal Enhancement of New Chemotherapeutic Agents at Moderate Hyperthermia
    Faheez Mohamed
    Pierre Marchettini
    O. Anthony Stuart
    M. Urano
    Paul H. Sugarbaker
    Annals of Surgical Oncology, 2003, 10 : 463 - 468
  • [36] Hypertension induced by chemotherapeutic and immunosuppresive agents: A new challenge
    Aad, Simon Abi
    Pierce, Matthew
    Barmaimon, Guido
    Farhat, Fadi S.
    Benjo, Alexandre
    Mouhayar, Elie
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2015, 93 (01) : 28 - 35
  • [37] SULFONYLUREAS - A NEW CLASS OF CANCER CHEMOTHERAPEUTIC-AGENTS
    MOHAMADI, F
    SPEES, MM
    GRINDEY, GB
    JOURNAL OF MEDICINAL CHEMISTRY, 1992, 35 (16) : 3012 - 3016
  • [38] Development of porous apatite ceramic for local delivery of chemotherapeutic agents
    Itokazu, M
    Sugiyama, T
    Ohno, T
    Wada, E
    Katagiri, Y
    JOURNAL OF BIOMEDICAL MATERIALS RESEARCH, 1998, 39 (04): : 536 - 538
  • [39] DEVELOPMENT OF INHIBITORS OF PROTEIN FARNESYLATION AS POTENTIAL CHEMOTHERAPEUTIC-AGENTS
    KOHL, NE
    CONNER, MW
    GIBBS, JB
    GRAHAM, SL
    HARTMAN, GD
    OLIFF, A
    JOURNAL OF CELLULAR BIOCHEMISTRY, 1995, : 145 - 150
  • [40] THE METHOTREXATE STORY - A PARADIGM FOR DEVELOPMENT OF CANCER CHEMOTHERAPEUTIC-AGENTS
    HUENNEKENS, FM
    ADVANCES IN ENZYME REGULATION, VOL 34, 1994, 34 : 397 - 419